Working with several countries authorities to tackle counterfeit versions of Ozempic: Novo Nordisk CEO

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-03-10 06:45 GMT | Update On 2024-03-20 10:23 GMT

Denmark: Novo Nordisk's CEO on Friday said the company was working with authorities in several countries to tackle counterfeit versions of its popular diabetes drug Ozempic, as new reports emerge of patient harm across the world.

"This is something we take very seriously," Lars Fruergaard Jorgensen, CEO of the Danish drugmaker, told Reuters.

The company has been testing suspect products and collaborates with authorities in the countries where counterfeits are found to assist in legal cases, he said. "We cannot take action on our own."

Surging demand for Novo's drugs that promote weight loss, known chemically as semaglutide, far outpaces supply, increasingly giving rise to concerns about unregulated and counterfeit medicines.

Counterfeit Ozempic has been found in as many as 16 countries to date, according to the Partnership for Safe Medicines, an anti-counterfeiting group.

Reports obtained in the last week by Reuters via Freedom of Information Act (FOIA) requests show patients were harmed after taking fake Ozempic in Belgium, Iraq, Serbia and Switzerland last year.

While Ozempic is approved for diabetes, it has the same active ingredient as Novo's powerful weight-loss drug Wegovy and has been used off-label for weight loss.

The World Health Organization has said global shortages of these drugs is linked to rising reports of suspected counterfeits. Last week, U.S. FDA head Robert Califf said there were likely more cases of online sales of fake obesity drugs than reported.

The reports, made by Novo to the U.S. Food and Drug Administration, showed that people suffered dangerous drops in blood sugar, called hypoglycemia, after taking suspected or confirmed fake versions of the drug. They add to previous confirmed reports of such cases in countries including Austria, Britain, Lebanon and the U.S.

INSULIN SOLD AS OZEMPIC

A report filed with the FDA on a 45 year-old woman in Belgium stated that she suffered a seizure and ended up in a diabetic coma after taking suspected fake Ozempic to lose weight. Her doctor said she had injected at least 18 doses of pure insulin, almost five times the recommended dose for someone with diabetes, the report showed.

The incident appears in the FDA's public adverse events reporting database, but the details were obtained by Reuters.

In a separate report, Novo Nordisk wrote that it investigated a suspected fake injector pen in Iraq and concluded it was possibly an Apidra Solostar insulin pen from French drugmaker Sanofi that had been relabeled.

The drugmaker told Reuters separately that it had found a Semglee insulin pen in the U.S. last June, made by Indian drugmaker Biocon, that had a suspected counterfeit Ozempic label glued onto it.

Jorgensen said he had also heard of cases in which insulin pens were relabeled and repackaged as Wegovy, noting that it's easier to print a box than develop a fake injector pen.

COMPOUNDING

Jorgensen, echoing comments from the FDA's Califf, also said compounded semaglutide in the United States was a serious health issue, and that the raw materials, or active pharmaceutical ingredients (API), for these products were coming from unregulated facilities in Asia and elsewhere.

"We don't know them, and we have really no insights or ability to understand what the API is in a certain compounded product," he said.

While fake drugs often do not contain any of the medication advertised, compounded drugs are custom-made medicines that are based on the same ingredients as branded drugs. Because Wegovy and Ozempic are in short supply, they can be legally produced by licensed pharmacies in the U.S.

Further reports obtained by Reuters through FOIA requests show that one person died last year from abnormal blood clotting after taking a drug that was advertised as compounded semaglutide. Three others suffered severe vomiting and nausea, sensory loss in their legs, and a drop in blood platelet levels.

The doctor whose patient died reported that the event was possibly linked to use of compounded semaglutide.

The Alliance for Pharmacy Compounding, which represents compounding pharmacists and technicians, did not respond to a request for comment but has said drugs that are not made at state-licensed pharmacies are not compounded medicines.

Original news source: https://www.reuters.com/business/healthcare-pharmaceuticals/compounded-semaglutide-poses-serious-us-health-issue-novo-nordisk-ceo-says-2024-03-08/

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Working with several countries authorities to tackle counterfeit versions of Ozempic: Novo Nordisk CEO

INSULIN SOLD AS OZEMPIC

COMPOUNDING

Similar News

NPPA Caps Prices of Ipratropium, Sodium Nitroprusside, Two Other Essential Drugs

Akum Pharma Asked to Submit Safety Data for Alzheimer's Drug Combo In Elderly Indian Patients

Aurobindo Pharma net profit drops 10 percent to Rs 824 crore in Q1

MSN Labs Gets CDSCO Panel Nod to Begin Phase III Trial of Cenobamate Tablets, With Safety Caveat

USFDA appoints Sean Keveney as Chief Counsel

Bristol Myers Squibb Breyanzi application accepted for priority review by USFDA for Marginal Zone Lymphoma

Cipla Bommasandra facility gets VAI classification from USFDA

Eli Lilly expands India presence with inauguration of Hyderabad site